What is Seekyo?
Seekyo Therapeutics is a pre-clinical stage biotechnology firm dedicated to pioneering Tumor Micro-Environment targeted therapies. Their core innovation, Tumor Activated Therapy, is designed to leverage the unique properties of tumors to trigger self-destruction, aiming to enhance the quality of life for cancer patients. The company has successfully validated the efficacy and safety of its therapeutic approaches in preclinical animal models and is actively advancing towards human proof of concept. Seekyo actively engages in collaborations with a spectrum of biotech and pharmaceutical partners to refine existing treatments and engineer novel therapeutic solutions for challenging oncological indications.
How much funding has Seekyo raised?
Seekyo has raised a total of $887K across 1 funding round:
Unspecified
$887K
Unspecified (2020): $887K with participation from BAdGE, INVESTESSOR, French Tech Seed Fund, SYNERGENCE, and European Investment Fund
Key Investors in Seekyo
European Investment Fund
The European Investment Fund (EIF) focuses on improving access to finance for small and medium-sized enterprises (SMEs) and infrastructure projects across Europe, offering a range of financial products including equity, debt, and guarantee products.
BAdGE
Undisclosed investor participating in the funding round.
INVESTESSOR
Undisclosed investor participating in the funding round.
What's next for Seekyo?
With the recent infusion of major strategic capital, Seekyo Therapeutics is poised to accelerate its transition from pre-clinical validation to human proof of concept. This enterprise-level funding is expected to fuel critical research and development initiatives, potentially enabling the company to advance its Tumor Activated Therapy towards clinical trials. The strategic nature of this investment suggests a strong alignment with partners looking to capitalize on novel oncology platforms, positioning Seekyo for significant growth and potential future pharmaceutical collaborations in the competitive landscape of cancer therapeutics.
See full Seekyo company page
